Topalov, N. E.
Mayr, D.
Kuhn, C.
Leutbecher, A.
Scherer, C.
Kraus, F. B. T.
Tauber, C. V.
Beyer, S.
Meister, S.
Hester, A.
Kolben, T.
Burges, A.
Mahner, S.
Trillsch, F.
Kessler, M.
Jeschke, U.
Czogalla, B.
Funding for this research was provided by:
Friedrich-Baur-Stiftung
Universitätsklinik München
Article History
Received: 22 October 2023
Accepted: 6 December 2023
First Online: 18 December 2023
Competing interests
: A.H. has received a research grant from the “Walter Schulz” foundation and advisory board, speech honoraria and travel expenses from Roche and Pfizer. T.K. holds stock of Roche, Biontech and Valneva and his relative is employed at Bayer. A.B. has received advisory board honoraria from AstraZeneca, Clovis, Roche and Tesaro. S.M. received research funding, advisory board, honorary or travel expenses from AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Hubro, Medac, MSD, Novartis, Nykode, Olympus, PharmaMar, Pfizer, Roche, Sensor Kinesis, Teva, and Tesaro. F.T. received research funding, advisory board honoraria and travel expenses from AstraZeneca, Clovis, Eisai, ImmunoGen, Medac, MSD, PharmaMar, Roche, and Tesaro/GSK. B.C. has received speech honoraria from AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.